+357 96 030922
info@marketpublishers.com

Global Non-Small Cell Lung Cancer Market Size study, by Type (Squamous Cell Carcinoma, Large Cell Carcinoma), Treatment (Chemotherapy, Immunotherapy), Distribution Channel and Regional Forecasts 2022-2032

https://marketpublishers.com/r/G912A56A0233EN.html
Date: May 2025
Pages: 285
Price: US$ 3,218.00 (Single User License)
ID: G912A56A0233EN

Abstracts

Global Non-Small Cell Lung Cancer (NSCLC) Market is valued approximately at USD 19.04 billion in 2023 and is anticipated to grow with a robust CAGR of more than 12.71% over the forecast period 2024–2032. Non-small cell lung cancer—accounting for nearly 85% of all lung cancer cases—has emerged as a dominant therapeutic area in oncology owing to rising prevalence, increased exposure to tobacco and environmental carcinogens, and improved early-stage diagnostic techniques. The market has witnessed a significant paradigm shift in treatment modalities, from conventional chemotherapy to precision-targeted therapies and immunotherapies that have substantially improved patient outcomes and survival rates. As the global burden of lung cancer continues to rise, especially in aging populations and urbanized regions, the demand for innovative NSCLC treatments is expected to climb steadily.

The market expansion is strongly driven by advancements in immuno-oncology, particularly the growing adoption of immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors. These agents have transformed treatment algorithms for advanced-stage NSCLC, offering improved progression-free survival with fewer toxicities than traditional regimens. Additionally, large pharmaceutical companies are increasingly investing in biomarker-specific drug development, targeting genetic mutations like EGFR, ALK, and KRAS. This evolution towards personalized medicine is supported by government initiatives and reimbursement frameworks in key markets, which have fostered early diagnostic testing and companion diagnostics to ensure treatment optimization. Furthermore, novel combination therapies that pair chemotherapy with immunotherapy

are gaining regulatory approvals, enhancing the therapeutic toolbox for oncologists globally.

Despite its promising trajectory, the NSCLC market still faces formidable challenges. Drug resistance—particularly in patients with EGFR mutations—remains a clinical hurdle, often necessitating second-line therapies and combination regimens. The high cost of biologics and immunotherapies continues to limit accessibility in lower-income regions, creating disparities in treatment availability. Moreover, stringent regulatory pathways, complex clinical trial designs, and safety monitoring requirements slow down drug development and commercialization timelines. However, increasing investments in real-world evidence (RWE) and AI-driven clinical research are helping streamline innovation pipelines and predict therapeutic efficacy more efficiently.

Technological advancements and strategic collaborations have emerged as cornerstones of growth within the NSCLC space. Pharmaceutical companies are forming alliances with diagnostic firms to co-develop targeted therapies, while digital health tools enable remote patient monitoring, side-effect management, and adherence tracking. The growing integration of genomic profiling into clinical practice is further driving demand for next-gen treatment protocols. Meanwhile, the shift toward outpatient care models and oral chemotherapy delivery systems is enhancing treatment convenience, especially among the elderly and those in remote geographies.

Regionally, North America leads the global NSCLC market due to early technology adoption, high healthcare expenditure, and established oncology care networks. The U.S., in particular, is home to many clinical trials, drug launches, and biopharmaceutical innovations. Europe follows closely, supported by national cancer control programs and rising uptake of immunotherapies across Germany, France, and the UK. Asia Pacific is expected to grow at the fastest pace during the forecast period, propelled by increasing smoking prevalence, air pollution, and improving cancer screening infrastructure in China, India, and Southeast Asian nations. Latin America and the Middle East & Africa are progressively integrating newer treatments through public-private partnerships and donor-backed healthcare reforms.

Major market player included in this report are:

Merck & Co., Inc.

AstraZeneca plc

Bristol-Myers Squibb Company

Hoffmann-La Roche Ltd.

Pfizer Inc.

Novartis AG

Sanofi S.A.

Eli Lilly and Company

Amgen Inc.

Takeda Pharmaceutical Company Limited

Bayer AG

Boehringer Ingelheim International GmbH

Daiichi Sankyo Company, Limited

Astellas Pharma Inc.

Teva Pharmaceutical Industries Ltd.

The detailed segments and sub-segment of the market are explained below:

By Type

Squamous Cell Carcinoma

Large Cell Carcinoma

By Treatment

Chemotherapy

Immunotherapy

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

+357 96 030922
info@marketpublishers.com

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

+357 96 030922
info@marketpublishers.com

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Companies Mentioned

Merck & Co., Inc.

AstraZeneca plc

Bristol-Myers Squibb Company

Hoffmann-La Roche Ltd.

Pfizer Inc.

Novartis AG

Sanofi S.A.

Eli Lilly and Company

Amgen Inc.

Takeda Pharmaceutical Company Limited

Bayer AG

Boehringer Ingelheim International GmbH

Daiichi Sankyo Company, Limited

Astellas Pharma Inc.

Teva Pharmaceutical Industries Ltd.

Contents

CHAPTER 1. GLOBAL NON-SMALL CELL LUNG CANCER MARKET EXECUTIVE SUMMARY

1.1. Global NSCLC Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
  1.3.1. By Type
  1.3.2. By Treatment
  1.3.3. By Distribution Channel
1.4. Key Trends
1.5. COVID-19 Impact
1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL NSCLC MARKET DEFINITION AND RESEARCH ASSUMPTIONS

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
  2.3.1. Inclusion & Exclusion
  2.3.2. Limitations
  2.3.3. Supply Side Analysis
    2.3.3.1. Manufacturing Capacity
    2.3.3.2. Infrastructure
    2.3.3.3. Regulatory Environment
    2.3.3.4. Competitive Landscape
    2.3.3.5. Economic Viability (Payer Perspective)
  2.3.4. Demand Side Analysis
    2.3.4.1. Reimbursement Frameworks
    2.3.4.2. Technological Advancements
    2.3.4.3. Patient Awareness & Access
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL NSCLC MARKET DYNAMICS

+357 96 030922
info@marketpublishers.com

3.1. Market Drivers
3.1.1. Rising Incidence of Lung Cancer & Early Diagnosis
3.1.2. Adoption of Immuno-Oncology Agents
3.1.3. Growth of Precision Medicine & Companion Diagnostics
3.2. Market Challenges
3.2.1. Therapeutic Resistance (EGFR, ALK Mutations)
3.2.2. High Treatment Costs & Access Disparities
3.3. Market Opportunities
3.3.1. Combination Regimens (Chemo + Immunotherapy)
3.3.2. AI-Driven Clinical Research & Real-World Evidence
3.3.3. Expansion in Emerging Oncology Markets

CHAPTER 4. GLOBAL NSCLC MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Future Outlook of Five Forces
4.1.7. Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL NSCLC MARKET SIZE & FORECASTS BY TYPE 2022-2032

5.1. Segment Dashboard
5.2. NSCLC Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)

+357 96 030922
info@marketpublishers.com

5.2.1. Squamous Cell Carcinoma
5.2.2. Large Cell Carcinoma

CHAPTER 6. GLOBAL NSCLC MARKET SIZE & FORECASTS BY TREATMENT 2022-2032

6.1. Segment Dashboard
6.2. NSCLC Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Chemotherapy
6.2.2. Immunotherapy

CHAPTER 7. GLOBAL NSCLC MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL 2022-2032

7.1. Segment Dashboard
7.2. NSCLC Market: Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Hospital Pharmacy
7.2.2. Retail Pharmacy
7.2.3. Online Pharmacy
7.2.4. Others

CHAPTER 8. GLOBAL NSCLC MARKET SIZE & FORECASTS BY REGION 2022-2032

8.1. North America NSCLC Market
8.1.1. U.S. NSCLC Market
8.1.1.1. Type Breakdown & Forecasts, 2022-2032
8.1.1.2. Treatment Breakdown & Forecasts, 2022-2032
8.1.2. Canada NSCLC Market
8.2. Europe NSCLC Market
8.2.1. UK NSCLC Market
8.2.2. Germany NSCLC Market
8.2.3. France NSCLC Market
8.2.4. Spain NSCLC Market
8.2.5. Italy NSCLC Market
8.2.6. Rest of Europe NSCLC Market
8.3. Asia Pacific NSCLC Market
8.3.1. China NSCLC Market
8.3.2. India NSCLC Market

+357 96 030922
info@marketpublishers.com

8.3.3. Japan NSCLC Market
8.3.4. Australia NSCLC Market
8.3.5. South Korea NSCLC Market
8.3.6. Rest of Asia Pacific NSCLC Market
8.4. Latin America NSCLC Market
8.4.1. Brazil NSCLC Market
8.4.2. Mexico NSCLC Market
8.4.3. Rest of Latin America NSCLC Market
8.5. Middle East & Africa NSCLC Market
8.5.1. Saudi Arabia NSCLC Market
8.5.2. South Africa NSCLC Market
8.5.3. Rest of Middle East & Africa NSCLC Market

CHAPTER 9. COMPETITIVE INTELLIGENCE

9.1. Key Company SWOT Analysis
9.1.1. Merck & Co., Inc.
9.1.2. AstraZeneca plc
9.1.3. Bristol-Myers Squibb Company
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Merck & Co., Inc.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. AstraZeneca plc
9.3.3. Bristol-Myers Squibb Company
9.3.4. Hoffmann-La Roche Ltd.
9.3.5. Pfizer Inc.
9.3.6. Novartis AG
9.3.7. Sanofi S.A.
9.3.8. Eli Lilly and Company
9.3.9. Amgen Inc.
9.3.10. Takeda Pharmaceutical Company Limited

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

TABLE 1. Global NSCLC market, report scope
TABLE 2. Global NSCLC market estimates & forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global NSCLC market estimates & forecasts by Type 2022-2032 (USD Billion)
TABLE 4. Global NSCLC market estimates & forecasts by Treatment 2022-2032 (USD Billion)
TABLE 5. Global NSCLC market estimates & forecasts by Distribution Channel 2022-2032 (USD Billion)
TABLE 6. Global NSCLC market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 7. North America NSCLC market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 8. Europe NSCLC market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. Asia Pacific NSCLC market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. Latin America NSCLC market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. Middle East & Africa NSCLC market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 12. U.S. NSCLC market estimates & forecasts by Type, 2022-2032 (USD Billion)
TABLE 13. U.S. NSCLC market estimates & forecasts by Treatment, 2022-2032 (USD Billion)
TABLE 14. Europe NSCLC market estimates & forecasts by Country, 2022-2032 (USD Billion)
TABLE 15. Asia Pacific NSCLC market estimates & forecasts by Country, 2022-2032 (USD Billion)
TABLE 16. Latin America NSCLC market estimates & forecasts by Country, 2022-2032 (USD Billion)
TABLE 17. Middle East & Africa NSCLC market estimates & forecasts by Country, 2022-2032 (USD Billion)
TABLE 18. Global NSCLC market competitive landscape (2023)
TABLE 19. Global NSCLC market patent filings & approvals by year
TABLE 20. Key clinical trial pipeline for NSCLC therapies

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

FIG 1. Global NSCLC market, research methodology
FIG 2. Global NSCLC market, market estimation techniques
FIG 3. Global NSCLC market size estimates & forecast methods
FIG 4. Global NSCLC market, key trends 2023
FIG 5. Global NSCLC market, growth prospects 2022-2032
FIG 6. Global NSCLC market, Porter’s five forces model
FIG 7. Global NSCLC market, PESTEL analysis
FIG 8. Global NSCLC market, value chain analysis
FIG 9. NSCLC market by Type, 2022 & 2032 (USD Billion)
FIG 10. NSCLC market by Treatment, 2022 & 2032 (USD Billion)
FIG 11. NSCLC market by Distribution Channel, 2022 & 2032 (USD Billion)
FIG 12. North America NSCLC market, 2022 & 2032 (USD Billion)
FIG 13. Europe NSCLC market, 2022 & 2032 (USD Billion)
FIG 14. Asia Pacific NSCLC market, 2022 & 2032 (USD Billion)
FIG 15. Latin America NSCLC market, 2022 & 2032 (USD Billion)
FIG 16. Middle East & Africa NSCLC market, 2022 & 2032 (USD Billion)
FIG 17. Global NSCLC market, company market share analysis (2023)
FIG 18. Global NSCLC market, R&D investment trends
FIG 19. Global NSCLC market, pricing analysis by region
FIG 20. Global NSCLC market, patient journey mapping
This Table of Contents is subject to change based on the final report structure.

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Non-Small Cell Lung Cancer Market Size study, by Type (Squamous Cell Carcinoma, Large Cell Carcinoma), Treatment (Chemotherapy, Immunotherapy), Distribution Channel and Regional Forecasts 2022-2032

Product link: https://marketpublishers.com/r/G912A56A0233EN.html

Price: US$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G912A56A0233EN.html